


CLAIMS

1. A compound of formula (I):



(I)

5

wherein

R¹ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, fluoroC₁₋₆alkyl, fluoroC₁₋₆alkoxy, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, NO₂, CN, SR^a, SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl substituted by C₁₋₄alkoxy, wherein R^a and R^b each independently represent hydrogen or C₁₋₄alkyl;

R² is hydrogen, halogen, C₁₋₆alkyl, fluoroC₁₋₆alkyl or C₁₋₆alkoxy substituted by C₁₋₄alkoxy;

R³ is hydrogen, halogen or fluoroC₁₋₆alkyl;

R⁴ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, fluoroC₁₋₆alkyl, fluoroC₁₋₆alkoxy, hydroxy, NO₂, CN, SR^a, SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl substituted by C₁₋₄alkoxy, wherein R^a and R^b are as previously defined;

R⁵ is hydrogen, halogen, C₁₋₆alkyl, fluoroC₁₋₆alkyl or C₁₋₆alkoxy substituted by C₁₋₄alkoxy;

R⁶ represents hydrogen or a C₁₋₄alkyl group optionally substituted by a hydroxy group;


R⁷ represents a 5- or 6-membered carbonyl or sulfonyl containing cyclic group comprising from 0 to 3 nitrogen ring atoms, from 0 to 1 oxygen ring atom

25

- and from 0 to 1 sulfur ring, wherein said ring is optionally substituted at any substitutable position by one or more substituents selected from =O, halogen, hydroxy, R¹¹, R¹², SR^f, SO₂R^g, COR^a, CO₂R^a, CONR⁹R¹⁰, -ZNR⁹R¹⁰, benzyl, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, fluoroC₁₋₄alkyl, chloroC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl,
- 5 C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, C₃₋₇cycloalkoxy, C₃₋₇cycloalkoxyC₁₋₄alkyl, C₁₋₄alkoxy, fluoroC₁₋₄alkoxy, hydroxyC₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkoxy, aryl, arylC₁₋₄alkyl, heteroaryl, heteroarylC₁₋₄alkyl or a 5- or 6-membered ring containing in the ring one oxygen atom or N(C₁₋₆alkyl), wherein R^f is C₁₋₄alkyl or aralkyl or aryl and R^g is C₁₋₄alkyl, aryl, arylC₁₋₄alkyl or NR⁹R¹⁰;
- 10 R⁸ represents hydrogen, C₁₋₆alkyl, fluoroC₁₋₆alkyl, hydroxy, C₁₋₆alkoxy, hydroxyC₁₋₆alkyl NR⁹R¹⁰, CONR⁹R¹⁰ or SO₂R^g;
- R⁹ is hydrogen, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, fluoroC₁₋₄alkyl, C₂₋₄alkyl substituted by a C₁₋₄alkoxy or hydroxyl group, or R⁹ is a five membered or six membered nitrogen-containing heteroaromatic ring as
- 15 previously defined;
- R¹⁰ is hydrogen or C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, fluoroC₁₋₄alkyl or C₂₋₄alkyl substituted by a C₁₋₄alkoxy or hydroxyl group;
- or R⁹, R¹⁰ and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two
- 20 groups selected from hydroxy, COR^e, CO₂R^e, C₁₋₄alkyl optionally substituted by a C₁₋₄alkoxy or hydroxyl group, or C₁₋₄alkoxy optionally substituted by a C₁₋₄alkoxy or hydroxyl group, or a five membered or six membered nitrogen-containing heteroaromatic ring as previously defined, or said heteroaliphatic ring is substituted by a spiro-fused lactone ring, and said heteroaliphatic ring optionally
- 25 containing a double bond, which heteroaliphatic ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)₂ or a second nitrogen atom which will be part of a NH or NR^d moiety, where R^d is C₁₋₄alkyl optionally substituted by hydroxy or C₁₋₄alkoxy;
- or R⁹, R¹⁰ and the nitrogen atom to which they are attached form a
- 30 non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
- or R⁹, R¹⁰ and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms to which is fused a benzene ring or a five membered or six membered nitrogen-containing heteroaromatic ring optionally containing 1, 2 or 3 additional heteroatoms selected from N, O and S;

R^{11} and R^{12} each independently represent hydrogen, hydroxy, COR^e , CO_2R^e , C_{1-4} alkyl optionally substituted by a C_{1-4} alkoxy or hydroxyl group, or C_{1-4} alkoxy optionally substituted by a C_{1-4} alkoxy or hydroxyl group;

or, when they are attached to the same carbon atom, R^{11} and R^{12} may together represent $=O$, $=CHCO_2R^a$, $-O(CH_2)_mO-$, $-CH_2O(CH_2)_k-$, $-CH_2OCH_2C(O)-$, $-CH_2OCH_2CH(OH)-$, $-CH_2OCH_2C(CH_3)_2-$, $-CH_2OC(CH_3)_2CH_2-$, $-C(CH_3)_2OCH_2CH_2-$, $-CH_2C(O)OCH_2-$, $-OC(O)CH_2CH_2-$, $-C(O)OCH_2CH_2-$, $-C(O)OC(CH_3)_2CH_2-$, $-C(O)OCH_2C(CH_3)_2-$, $-OCH_2(CH_2)_k-$, $-OC(CH_3)_2CH_2CH_2-$, $-OCH_2C(CH_3)_2CH_2-$, $-OCH_2CH_2C(CH_3)_2-$, $-OCH_2CH=CHCH_2-$, $-OCH_2CH(OH)CH_2CH_2-$, $-OCH_2CH_2CH(OH)CH_2-$, $-OCH_2C(O)CH_2CH_2-$, $-OCH_2CH_2C(O)CH_2-$, or a group of the formula



or, where they are attached to adjacent carbon atoms, R^{11} and R^{12} may together represent $-OCH_2CH_2-$ or $-OCH_2CH(OH)-$, or R^{11} and R^{12} may together form a fused benzene ring;

or, R^{11} and R^{12} together form a C_{1-2} alkylene bridge across the pyrrolidine, piperidine, morpholine or piperazine ring to which they are attached;

R^{13} represents hydrogen, phenyl, benzyl, pyridyl, tetrahydropyranyl, piperidinyl, N-substituted piperidinyl (where the N-substituent is C_{1-6} alkyl), C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, $-SO_2C_{1-4}$ alkyl or C_{2-4} alkyl substituted by a C_{1-4} alkoxy or hydroxyl group;

R^{14} represents hydrogen, halogen, hydroxy, C_{1-4} alkyl, hydroxy C_{1-4} alkyl or fluoro C_{1-4} alkyl;

R^{15} and R^{16} each independently represent hydrogen, halogen, C_{1-6} alkyl, CH_2OR^c , oxo, CO_2R^a or $CONR^aR^b$ where R^a and R^b are as previously defined and R^c represents hydrogen, C_{1-6} alkyl or phenyl;


Z represents a bond, C_{1-6} alkylene or C_{3-6} cycloalkylene;

k is 1, 2 or 3;

m is 1 or 2; and

n is zero, 1 or 2;

with the proviso that when n is zero and R⁸ is hydrogen, R⁷ does not represent a C-linked nitrogen-containing ring of the formula



5

wherein

A represents NR¹³, and B represents a bond, CH₂, NR¹³ or O, wherein one or both hydrogen atoms in said CH₂ moiety may be replaced with one or both of R¹¹ and R¹², or alternatively, one of the hydrogen atoms in said CH₂ moiety together with a hydrogen atom from an adjacent carbon are replaced by a double bond; or A is O, and B is NR¹³; and R¹¹ and R¹² together represent =O; and pharmaceutically acceptable salts thereof.

2. A compound according to Claim 1 wherein R¹ is hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halogen or CF₃.

3. A compound according to Claim 1 or Claim 2 wherein R² is hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halogen or CF₃.


4. A compound according to any one of Claims 1 to 3 wherein R³ is hydrogen, fluorine, chlorine or CF₃.

5. A compound according to any one of Claims 1 to 4 wherein R⁴ is hydrogen or fluorine.


6. A compound according to any one of Claims 1 to 5 wherein R⁵ is hydrogen, fluorine, chlorine or CF₃.

7. A compound according to any one of Claims 1 to 6 wherein R⁶ is C₁₋₄alkyl optionally substituted by hydroxy.


8. A compound according to any one of Claims 1 to 7 wherein R^7 is a cyclic group selected from the group consisting of:




X is N, CH or CH_2




X is O or CH_2
n is 1 or 2




X is O, NH, CH_2 or NR^{13}
n is 1 or 2







X is NH or CH_2





X is O, NH, CH_2 or NR^{13}
n is 1 or 2




X is O, NH, CH_2 or NR^{13}
n is 1 or 2




5





X is NR^{13} or CH_2



X is NR^{13} or CH_2





X is NR^{13} or CH_2




X is NR^{13} , O or SO_2


- 48 -




X is N or CH



X is N or CH





and




X is N or CH

wherein R^{13} is as defined in Claim 1, and further wherein any of said cyclic groups is optionally substituted by one or more groups as defined in Claim 1.

- 5 9. A compound according to any one of Claims 1 to 7 wherein R^7 is a cyclic group selected from the group consisting of:



and



- 10 wherein R^{13} is as defined in Claim 1, and further wherein any of said cyclic groups is optionally substituted by one or more groups as defined in Claim 1.

- 10 10. A compound according to any one of Claims 1 to 9 wherein R^8 is hydrogen or methyl.

- 15 11. A compound according to any one of Claims 1 to 10 wherein R^{12} is hydrogen, hydroxy, C_{1-2} alkyl substituted by hydroxy, C_{1-4} alkoxy or CO_2R^e (where R^e is hydrogen, methyl ethyl or benzyl).


12. A compound according to any one of Claims 1 to 11 wherein R^{13} represents hydrogen, methyl or ethyl.

5 13. A compound according to any one of Claims 1 to 12 wherein R^{15} and R^{16} are both hydrogen atoms.

14. A compound according to any one of Claims 1 to 13 wherein n is zero or 1.

10

15. A compound according to Claim 1 of the formula (Ia):



15 wherein

A^1 is fluorine or CF_3 ;

A^2 is fluorine or CF_3 ;

A^3 is fluorine or hydrogen;

A^4 is fluorine or hydrogen;

20 A^5 is methyl; and

R^7 and n are as defined in Claim 1;

or a pharmaceutically acceptable salt thereof.

- 50 -

16. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 15, together with at least one pharmaceutically acceptable carrier or excipient.

5 17. A compound according to any of claims 1 to 15 for use in a method of treatment of the human body.

18. A method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, which method comprises
10 administration to a patient in need thereof of a tachykinin reducing amount of a compound according to Claim 1.

19. A method for the treatment or prevention of pain or inflammation, migraine, emesis, postherpetic neuralgia, depression or anxiety, which method
15 comprises administration to a patient in need thereof of a therapeutically effective amount of a compound according to Claim 1.

20. Use of a compound as claimed in any one of Claims 1 to 15 for the manufacture of a medicament for the treatment or prevention of physiological
20 disorders associated with an excess of tachykinins.

21. Use of a compound as claimed in any one of Claims 1 to 15 for the manufacture of a medicament for the treatment or prevention of pain or inflammation, migraine, emesis, postherpetic neuralgia, depression or anxiety.
25